Cybin (HELP) Depreciation & Amortization (CF) (2020 - 2025)
Cybin (HELP) reported Depreciation & Amortization (CF) of $43208.8 for Q1 2025, down 59.0% on a YoY basis from $105380.1 in Q1 2024, and down 54.27% quarter-over-quarter from $94492.1 in Q4 2024.
Cybin (HELP) Depreciation & Amortization (CF) (2020 - 2025) Analysis & Trends
Cybin has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $43208.8 in Q1 2025.
- For the quarter ending Q1 2025, Depreciation & Amortization (CF) fell 59.0% year-over-year to $43208.8; the trailing twelve-month figure through Jun 2025 stood at $242527.5 (down 33.29% YoY), and the FY2025 full-year result was $341695.1, up 8.59% from the prior year.
- Depreciation & Amortization (CF) for Q1 2025 stood at $43208.8, down from $94492.1 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $105380.1 in Q1 2024, with the low at -$56037.0 in Q1 2023.
- Historically, Depreciation & Amortization (CF) has averaged $50530.7 across 5 years, with a median of $48302.6 in 2022.
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) surged 250.06% — and 2023, when it slumped 1051.88%.
- Cybin's Depreciation & Amortization (CF) stood at $34906.8 in 2021, then surged by 49.84% to $52305.9 in 2022, then surged by 99.41% to $104304.0 in 2023, then retreated by 9.41% to $94492.1 in 2024, then tumbled by 54.27% to $43208.8 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $43208.8 (Q1 2025), $94492.1 (Q4 2024), and $104826.6 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 43,208.82 |
| Mar 31, 2025 | 43,208.82 |
| Dec 31, 2024 | 94,492.09 |
| Dec 31, 2024 | 94,492.09 |
| Sep 30, 2024 | 104,826.64 |
| Sep 30, 2024 | 104,826.64 |
| Jun 30, 2024 | 100,897.40 |
| Jun 30, 2024 | 100,897.40 |
| Mar 31, 2024 | 105,380.08 |
| Mar 31, 2024 | 105,380.08 |
| Dec 31, 2023 | 104,304.04 |
| Dec 31, 2023 | 104,304.04 |
| Sep 30, 2023 | 52,961.06 |
| Sep 30, 2023 | 52,961.06 |
| Jun 30, 2023 | 51,367.22 |
| Jun 30, 2023 | 51,367.22 |
| Feb 28, 2023 | -56,036.99 |
| Feb 28, 2023 | -56,036.99 |
| Dec 31, 2022 | 52,305.91 |
| Dec 31, 2022 | 52,305.91 |